IGF1 and Hypoglycemia: The Ea moiety in the IGF-1Ea propeptide, which is efficiently cleaved, anchors IGF-1 to the extracellular matrix in other tissues preventing its clearance and reducing off-target effects.23 This feature dampens the risks associated with elevated systemic IGF-1 levels such as hypotension34 and hypoglycaemia.35